Volume 4.19 | May 17

Mammary Cell News 4.19 May 17, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Ganglioside GD2 Identifies Breast Cancer Stem Cells and Promotes Tumorigenesis
Scientists identified ganglioside GD2 as a new cancer stem cell (CSC)-specific cell surface marker and GD3 synthase as a potential therapeutic target for CSCs, with the possibility of improving survival and cure rates in patients with breast cancer. [J Clin Invest] Full Article | Press Release

Apply Now: Mammary Stem Cell Training Course (June 2-3 2012) in Vancouver, Canada.
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Fra-1 Promotes Breast Cancer Chemosensitivity by Driving Cancer Stem Cells from Dormancy
Findings suggest that Fra-1 may be an important prognostic marker for breast cancer therapy. [Cancer Res]
Abstract

Prolyl Isomerase Pin1 Downregulates Tumor Suppressor RUNX3 in Breast Cancer
Researchers identified prolyl isomerase Pin1 as a new regulator of RUNX3 inactivation in breast cancer. [Oncogene] Abstract

LASS2 Enhances Chemosensitivity of Breast Cancer by Counteracting Acidic Tumor Microenvironment through Inhibiting Activity of V-ATPase Proton Pump
Findings suggest that LASS2 is involved in chemotherapeutic outcomes and low LASS2 expression may predict chemoresistance. [Oncogene] Abstract

GDC-0941, A Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Researchers determined if GDC-0941 enhances the anti-tumor activity of Docetaxel in human breast cancer models in vitro and in vivo. [Clin Cancer Res] Abstract

PET of HER2-Positive Pulmonary Metastases with 18F-ZHER2:342 Affibody in a Murine Model of Breast Cancer: Comparison with 18F-FDG
Scientists compared the use of a human epidermal growth factor receptor 2 (HER2)-specific 18F-ZHER2:342-Affibody and 18F-FDG in HER2-expressing pulmonary metastases in a murine model of breast cancer. [J Nucl Med] Abstract

Downregulation of the Tumor-Suppressor miR-16 via Progestin-Mediated Oncogenic Signaling Contributes to Breast Cancer Development
Investigators revealed the first progestin-regulated microRNA (miRNA) expression profile and identified a novel role for miR-16 as a tumor suppressor in progestin- and growth factor-induced growth in breast cancer. [Breast Cancer Res] Full Article

Stromal Adipocyte PPARγ Protects against Breast Tumorigenesis
Data suggest that in vivo peroxisome proliferator-activated receptor γ (PPARγ) expression in mammary stromal adipocyte attenuates breast tumorigenesis through BRCA1 upregulation and decreased leptin secretion. [Carcinogenesis] Abstract

Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Scientists demonstrated feasibility of performing high dimensional single circulating tumor cell (CTC) profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery. [PLoS One] Full Article

CLINICAL RESEARCH

Five-Year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy with an Incorporated Boost for Early Stage Breast Cancer
Scientists report the five-year results of a phase II study of intensity modulated radiation therapy, hypofractionation, and incorporated boost that shortened treatment time to four weeks. [Int J Radiat Oncol Biol Phys] Abstract

CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
To understand the impact of daclizumab on regulatory T cells in vivo, researchers performed a clinical trial of daclizumab in combination with an experimental cancer vaccine in patients with metastatic breast cancer. [Sci Transl Med] Abstract | Press Release

Don't Lose Sleep Over Mouse Mammary Tissue Dissociation (New Enzymes: Learn More)

INDUSTRY NEWS

Grant to Fund Use of Kinase Test in HER2-Positive Breast Cancer
Susan G. Komen for the Cure® has awarded a grant of almost $900,000 to Lisa A. Carey, MD, and Gary Johnson, PhD, to research clinical applications for the first broad-based test for protein kinase activation and response to inhibitory drugs in HER2-positive breast cancer. [University of North Carolina Health Care System] Press Release

Collaborative Study Looks for Clues on Hard-to-Treat Breast Cancer
Triple negative breast cancer is the focus of a 20-month, $8.6-million research project that aims to find new diagnostic tools and options for drugs. [EurekAlert!] Press Release

NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay
NanoString Technologies, Inc. announced the initiation of the second clinical validation study of its PAM50-based breast cancer assay. [NanoString Technologies, Inc.] Press Release

Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
Generex Biotechnology Corporation announced that the expertise of the Scientific Advisory Board of Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical trial research and immuno-therapeutic treatments of breast cancer. [Generex Biotechnology Corporation] Press Release

POLICY NEWS

A Global Standard for Peer Review
After winning the strong backing of the White House, Subra Suresh convened a meeting of 47 leaders of research funding agencies from 44 countries. At the conclusion of closed-door sessions, the group will issue the first-ever global statement on the principles of merit review. [National Science Foundation, United States]
Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW American Association for Cancer Research (AACR): Translational Cancer Research for Basic Scientists
November 26-December 1, 2012
Boston, United States

Visit our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)


Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)


Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Postdoctoral Position – Breast Cancer Biology (Bellvitge Institute for Biomedical Research)

Postdoc Positions – Molecular Cancer Biology (Baylor College of Medicine)

Postdoctoral Position – Breast Cancer Research (Beckman Research Institute)

Research Fellowship – Transformed Signal Transduction Networks in Breast Cancer (Memorial Sloan-Kettering Cancer Center)



Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us